<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095935</url>
  </required_header>
  <id_info>
    <org_study_id>PSR Surgical</org_study_id>
    <nct_id>NCT05095935</nct_id>
  </id_info>
  <brief_title>Medtronic PSR Signia SDR</brief_title>
  <official_title>Medtronic Signia Small Diameter Reload Product Surveillance Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the registry is to confirm the safety and performance of the Signiaâ„¢ Small&#xD;
      Diameter Reload (SDR) when used in surgical procedures in a real-world setting in patients&#xD;
      receiving surgery for indicated thoracic, abdominal, and pediatric applications,&#xD;
      intraoperatively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Incidence of intraoperative hemostatic intervention</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of repeat hospital admission for primary procedure-related complications</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative assessments: Assessment of staple line integrity using a five-point Likert scale</measure>
    <time_frame>30 days</time_frame>
    <description>Range from 1 (no bleeding) to 5 (significant bleeding requiring intervention)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative assessments: Incidence of staple line bleeding (measured as &gt; 50cc)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative assessments: Additional intervention(s) to treat staple line failure</measure>
    <time_frame>30 days</time_frame>
    <description>Additional interoperative interventions to treat staple line failure (Applying additional stapler reloads, Applying compression greater than what is considered typical, Over-sewing with suture, Placing clips, Use of energy, Use of seatbelt, Other)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative assessments: Additional intervention(s) to treat staple-line failure</measure>
    <time_frame>30 days</time_frame>
    <description>Additional postoperative interventions to treat staple line failure (Applying additional stapler reloads, Applying compression greater than what is considered typical, Over-sewing with suture, Placing clips, Use of energy, Use of seatbelt, Other)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Minimally Invasive Surgical Procedures</condition>
  <condition>Surgical Procedures, Operative</condition>
  <arm_group>
    <arm_group_label>Thoracic Adult</arm_group_label>
    <description>Use of Signia SDR for the transection of pulmonary arteries and veins in adult patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abdominal Adult</arm_group_label>
    <description>Use of Signia SDR for the transection of renal arteries and veins in adult patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abdominal Pediatric</arm_group_label>
    <description>Use of Signia SDR for the transection of the appendiceal stump and mesoappendix (simple acute appendicitis) in pediatric patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>N/A observational registry</intervention_name>
    <description>N/A observational registry</description>
    <arm_group_label>Abdominal Adult</arm_group_label>
    <arm_group_label>Abdominal Pediatric</arm_group_label>
    <arm_group_label>Thoracic Adult</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing surgical procedures during which the Signia Small Diameter Reload is&#xD;
        being used for transection of the arteries and veins meeting the cohort criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient or legally authorized representative (LAR) provides authorization and/or&#xD;
             consent per institution and geographical requirements&#xD;
&#xD;
          -  Patient has, or is intended to receive or be treated with, an eligible Medtronic&#xD;
             product&#xD;
&#xD;
          -  Patient is consented within the enrollment window of the therapy received, as&#xD;
             applicable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who is, or is expected to be, inaccessible for follow-up&#xD;
&#xD;
          -  Patient is excluded by local law&#xD;
&#xD;
          -  Patient is currently enrolled in, or plans to enroll in, any concurrent drug/device&#xD;
             study that may confound the PSR results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>PSR Study Team</last_name>
    <phone>1-800-633-8766</phone>
    <email>rs.productsurveillanceregistry@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Health Systems</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

